162
Views
6
CrossRef citations to date
0
Altmetric
Research Article

Daily-diary Evaluated Side Effects of Dose-escalation Radiotherapy of Prostate Cancer Using the Stereotactic Beamcath®R; Technique

, , , , &
Pages 326-333 | Published online: 08 Jul 2009

  • Pollack A, Zagars GK, Starkschall G, et al. Conventional vs. conformai radiotherapy for prostate cancer: preliminary results of dosimetry and acute toxicity. Int J Radiat Oncol Biol Phys 1996; 34: 555-64.
  • Widmark A, Fransson P, Franzen L, Littbrand B, Henriksson R. Daily-diary evaluated side effects of conformai versus conventional prostatic cancer radiotherapy technique. Acta Oncol 1997; 36: 499-507.
  • Dearnaley DP, Khoo VS, Norman AR, et al. Comparison of radiation side-effects of conformai and conventional radiotherapy in prostate cancer: a randomised trial [see comments]. Lancet 1999; 353: 267-72.
  • Sandier HM, McLaughlin PW, Ten Haken RK, Addison H, Forman J, Lichter A. Three dimensional conformai radiotherapy for the treatment of prostate cancer: low risk of chronic rectal morbidity observed in a large series of patients. Int J Radiat Oncol Biol Phys 1995; 33: 797-801.
  • Roach III M, Pickett B, Weil M, Verhey L. The 'critical volume tolerance method' for estimating the limits of dose escalation during three-dimensional conformai radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 1996; 35: 1019-25.
  • Pollack A, Zagars OK. External beam radiotherapy dose response of prostate cancer. Int J Radiat Oncol Biol Phys 1997; 39: 1011-8.
  • Hanks GE, Hanlon AL, Schultheiss TE, Pinover WH, Movsas B, Epstein BE, et al. Dose escalation with 3D conformai treatment: five year outcomes, treatment optimization, and future directions. Int J Radiat Oncol Biol Phys 1998; 41: 501-10.
  • Zelefsky MJ, Leibel SA, Kutcher GJ, Fuks Z. Three-dimensional conformai radiotherapy and dose escalation: where do we stand? Semin Radiat Oncol 1998; 8: 107-14.
  • Pollack A, Zagars GK, Smith LG, et al. Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 G with 78 Gy for prostate cancer. J Clin Oncol 2000; 18: 3904-11.
  • Sandier HM, Ferez Tamayo C, Ten Haken RK, Lichter AS. Dose escalation for stage C (T3) prostate cancer: minimal rectal toxicity observed using conformai therapy. Radiother Oncol 1992; 23: 53-4.
  • Lee WR, Hanks GE, Hanlon AL, Schultheiss TE, Hunt MA. Lateral rectal shielding reduces late rectal morbidity following high dose three-dimensional conformai radiation therapy for clinically localized prostate cancer: further evidence for a significant dose effect [see comments]. Int J Radiat Oncol Biol Phys 1996; 35: 251-7.
  • Bergström P, Löfroth P-O, Widmark A. High-precision conformal radiotherapy (HPCRT) of prostate cancer--a new technique for exact positioning of the prostate at the time of treatment. Int J Radiat Oncol Biol Phys 1998; 42: 305-11.
  • Fransson P, Löfroth P-O, Franzen L, Henriksson R, Bergström P, Widmark A. Acute side effects after dose-escalation treatment of prostate cancer using the new urethral catheter BeamCath technique. Acta Oncol 2001; 40: 756-65.
  • Henriksson R, Franzen L, Littbrand B. Effects of sucralfate on acute and late bowel discomfort following radiotherapy of pelvic cancer. J Clin Oncol 1992; 10: 969-75.
  • Landberg T, Chavaudra J, Dobbs J, et al. ICRU REPORT 50. Prescribing, recording and reporting photon beam therapy. Int Comm Radiat Units Measure 1993.
  • Zelefsky MJ, Leibel SA, Gaudin PB, et al. Dose escalation with three-dimensional conformai radiation therapy affects the outcome in prostate cancer [see comments]. Int J Radiat Oncol Biol Phys 1998; 41: 491-500.
  • Boersma LJ, van den Brink M, Bruce AM, et al. Estimation of the incidence of late bladder and rectum complications after high-dose (70-78 Gy) conformai radiotherapy for prostate cancer, using dose-volume histograms. Int J Radiat Oncol Biol Phys 1998; 41: 83-92.
  • Roach III M. Comparison of treatment techniques for conformal radiotherapy of the prostate using dose-volume histograms and normal tissue complication probabilities [letter]. Radiother Oncol 1996; 40: 85-7.
  • Zelefsky MJ, Harrison A. Neoadjuvant androgen ablation prior to radiotherapy for prostate cancer: reducing the potential morbidity of therapy. Urology 1997; (Suppl): 3845.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.